Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
University of Alberta
Headquarters: Edmonton, AB, Canada
Website: http://www.ualberta.ca
Year Founded: 1908
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Sep 26, 2024
Discovery & Translation
Science Spotlight: Targeted protein relocalization, rejuvenating aged eggs, and more
BioCentury’s roundup of translational innovations
BioCentury | May 16, 2023
Emerging Company Profile
Ray: a genotype-agnostic approach to reversing blindness with one-time therapy
With $100M in series A funding, ‘2.0’ gene therapy company aims to treat retinitis pigmentosa using a channelrhodopsin variant designed for greater light sensitivity
BioCentury | Jun 14, 2022
Product Development
Poxvirus agents, by the mechanisms
The mechanisms of products approved for monkeypox and other orthopoxviruses offer the potential for combinations
BioCentury | Jan 1, 2021
Targets & Mechanisms
A snapshot of target innovation in 2020
An analysis of BioCentury’s Distillery captures trends from preclinical publications in 2020
BioCentury | Oct 24, 2020
Translation in Brief
UNC Chapel Hill Angelman gene therapy rescues motor function; plus data backing planned Pacylex, Kronos clinical trials and more
BioCentury’s roundup of translational news
BioCentury | Aug 27, 2020
Distillery Therapeutics
Antisense oligos against transcription factor DUX4 for a muscular dystrophy
DISEASE CATEGORY: Musculoskeletal
INDICATION: Muscular dystrophy Antisense oligonucleotide therapies targeting DUX4 could treat facioscapulohumeral muscular dystrophy (FSHD), which is caused by
INDICATION: Muscular dystrophy Antisense oligonucleotide therapies targeting DUX4 could treat facioscapulohumeral muscular dystrophy (FSHD), which is caused by
BioCentury | Jun 4, 2020
Product Development
WHO restarts hydroxychloroquine testing as drug fails another COVID-19 trial
Editors flag ‘serious’ concerns regarding validity of data in Lancet paper
BioCentury | Apr 29, 2020
Emerging Company Profile
Rome: tackling repeat DNA for cancer, autoimmunity
Rome launches with $50M series A round to leverage repeat biology
BioCentury | Dec 5, 2019
Emerging Company Profile
VaxNewMo: bioconjugating antibacterial vaccines
VaxNewMo’s platform could yield new, less costly glycoconjugate vaccines
BioCentury | Jun 18, 2019
Distillery Therapeutics
APLN17 analog identified for abdominal aortic aneurysm
Items per page:
1 - 10 of 99